Press Releases

NetNoggin® releases exploratory analysis "Psychographics for TRIKAFTA™"

image185

 FREDERICK, Md., Dec. 12, 2019 /PRNewswire/ -- A new exploratory study, conducted by NetNoggin®, highlights the attitudes and beliefs of patients and caregivers regarding the approval of TRIKAFTA™ in the cystic fibrosis market.  NetNoggin® is also updating their syndicated report, NetNog: #genesis® Cystic Fibrosis, to reflect these changes in the market due to TRIKAFTA™.  NetNoggin® will continue to follow the patient journey disruption from January 1, 2020 to June 30, 2020. 

NetNoggin® releases exploratory analysis "Healthcare Provider Needs in the NASH Market"

image186

 FREDERICK, Md., Nov. 7, 2019 /PRNewswire/ -- An exploratory study, conducted by NetNoggin®, revealed healthcare providers (HCPs) in the nonalcoholic steatohepatitis (NASH), including nonalcoholic fatty liver (NAFL), market have multiple unmet needs within: research of NASH (including NAFL), pediatric nonalcoholic fatty liver disease (NAFLD), diagnosis and screening, treatment and management protocols, and education and awareness for patients and the general community.

image187

NetNoggin® releases exploratory analysis "Alzheimer's Recent Drug Failures"

image188

 FREDERICK, Md., Oct. 2, 2019 /PRNewswire/ -- An exploratory study, conducted by NetNoggin®, revealed that among those impacted by Alzheimer's, hope of finding a cure is deflating due to recent Alzheimer's clinical trial failures in the past few years. 

NetNoggin® releases results from "Levels of Caregiving for Patients with Alzheimer's Disease"

image189

 FREDERICK, Md., July 17, 2019 /PRNewswire/ -- NetNoggin® released detailed results from a netnographic-qualitative research study, which investigated levels of caregiving for patients with Alzheimer's disease and was presented at the Alzheimer's Association International Conference® (AAIC) 2019, held in Los Angeles, California, July 14 – 18.  

NetNoggin® releases results from "Utilization of Technology in Alzheimer's Disease"

image190

 FREDERICK, Md., July 16, 2019 /PRNewswire/ -- NetNoggin® released detailed results from a netnographic-qualitative research study, which investigated the utilization of technology in Alzheimer's disease (including mild cognitive impairment [MCI]), presented at the Alzheimer's Association International Conference® (AAIC) 2019 held in Los Angeles, California, July 14 - 18. 

NetNoggin® announces the release of NetNog: #genesis® NASH (including NAFL)

image191

 

FREDERICK, Md., May 21, 2019 /PRNewswire/ -- NetNoggin®, a premier market research agency that specializes in pharmaceutical marketing, has announced the release of its newest research, NetNog: #genesis® Nonalcoholic Steatohepatitis (NASH) (including Nonalcoholic Fatty Liver [NAFL]). 

NetNoggin® research to be presented at the 2019 Alzheimer's Association International Conference

image192

 FREDERICK, Md., April 4, 2019 /PRNewswire/ -- NetNoggin® announced they will present additional findings from their Alzheimer's disease research report at the upcoming Alzheimer's Association International Conference (AAIC®). 

NetNoggin® announces the release of NetNog: #genesis® Cystic Fibrosis Patient and Caregiver Journeys

image193

 FREDERICK, Md., Feb. 26, 2019 /PRNewswire/ -- In honor of Rare Disease Day on Thursday, NetNoggin®, a premier market research agency that specializes in pharmaceutical marketing, has announced the release of its newest offering, NetNog: #genesis® Cystic Fibrosis Patient and Caregiver Journeys. 

NetNoggin® announces the release of NetNog: #genesis® Alzheimer's Disease (incl. MCI)

image194

 FREDERICK, Md., Nov. 8, 2018 /PRNewswire/ -- NetNoggin®, a premier market research agency that specializes in pharmaceutical marketing, has announced the release of its newest research, NetNog: #genesis® Alzheimer's Disease (including Mild Cognitive Impairment [MCI]) 

NetNoggin® announces the release of NetNog: #genesis® Cystic Fibrosis research

image195

 FREDERICK, Md., Oct. 19, 2018 /PRNewswire/ -- NetNoggin®, a premier market research agency that specializes in pharmaceutical marketing, has announced the release of its newest research, NetNog: #genesis® Cystic Fibrosis. 

NetNoggin® announces the release of NetNog: #genesis®

image196

 FREDERICK, Md., Oct. 17, 2018 /PRNewswire/ -- NetNoggin® has released its newest product, NetNog: #genesis®, offering pharmaceutical companies unmatched insights into their patients' and caregivers' real world lexicon, unmet needs, treatment flow process, and journey.